Xeris Biopharma Holdings, Inc. XERS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s financing cash flow?
- Xeris Biopharma Holdings, Inc. (XERS) reported financing cash flow of -$8.84M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s financing cash flow changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s financing cash flow decreased by 181.7% year-over-year, from -$3.14M to -$8.84M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s financing cash flow?
- Over 2 years (2021 to 2024), Xeris Biopharma Holdings, Inc.'s financing cash flow has grown at a 15.3% compound annual growth rate (CAGR), from $27.25M to $36.25M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.